|
Post by pguererro on Oct 22, 2017 21:16:27 GMT -5
When pharma “lays off” they don’t make their decisions based on sales performance, tenure etc. They stopped doing that 15yrs ago. They now lay off segments of sales forces to avoid any liability. So many times top performers with long successful sales performance history are caught being in the segment of reps being laid off. It’s also a way they can downsize and get rid of huge base salaries from long time high performers only to “expand” 1-2 yrs later hiring kids right out of college at less than half the base salary.
|
|
|
Post by babaoriley on Oct 22, 2017 21:38:43 GMT -5
Someone with a huge salary is going to find it tough to make ends meet with just Afrezza. Let's not go overboard here, let's see what plays out. Foreign sales would be very welcome.
|
|
|
Post by racedog on Oct 23, 2017 7:45:37 GMT -5
Things are very unclear to me, we are now progressing into some mercky waters. Merck needs us. They just basically lost their shingles drug. See off topic What about Celgene. They just lost Mongersen.
|
|
|
Post by itellthefuture777 on Oct 23, 2017 11:36:06 GMT -5
$490 billion in drugs started losing their patents in 2012. It is a sellers market as large pharma realigns. They may look to repurpose their drugs to an inhaled version to show superiority from the old form. Also big pharma sales forces will naturally be lead to Mannkind as if handed to them by big pharma. Looking at Merck one could imagine adding 10x to 100x the sales force to MNKD which would be like 70x to 700x a Sanofi work force in sales. Plus...adding the ability of PCP to prrscribe verses just endo's will break the back in sales records imo as there are only 8k endo's in the U.S. and 100's of thousands of PCP's...That said with all those drugs falling off the patent cliff...along with their BP's...I am betting they have made offers..already..but have been told no..as values increase for MNKD..and more players enter the field..I can imagine a huge bidding war..in the billions!
|
|
|
Post by liane on Oct 23, 2017 12:16:14 GMT -5
itellthefuture777 I understand your excitement, but please refrain from the unrealistic pumping.
|
|
|
Post by itellthefuture777 on Oct 23, 2017 12:28:34 GMT -5
I am going to take issue with the thought that Afrezza alone isn't worth billions in a buyout scenario when $1 Billion was handed over by Sanofi before the new label for 65%. The discussion in this thread is about drugs going off patent. When I am excited my thoughts on the stock are above $4k a share..so when I am just saying Billions without a number you shouldn't take that as a pump but a realistic speculative based on the aforementioned partnership. If you think Mannkind is not set to sell Afrezza in a co-promotion that is ok..I think they will be in a co-promotion and that is also ..ok. Also I think given Al Mann's history it is also ok to speculate on the sale of Mannkind or the Drug Afrezza to a large Pharma. This is my one post today and can not hardly be considered pumping ..just a positive comment at best. On comments I found this one interesting
"We are extremely proud of this new device, which is just one example of our commitment to improving the ease of administration of treprostinil therapy so that more patients can benefit from our medicine," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "We are not resting on our laurels with this device, however. We recently launched a new program to develop a small, metered dose inhalation device for treprostinil, and are planning to study the administration of inhaled treprostinil on a pro re nata 'as needed' basis, to provide more flexibility for patients to use inhaled treprostinil where they need it, when they need it. And of course, we are continuing the development of our advanced delivery devices for Remodulin®, such as our RemUnity™ subcutaneous pump, and RemoPro™, a prodrug formulation of treprostinil." www.cnbc.com/2017/10/23/pr-newswire-united-therapeutics-announces-fda-approval-of-third-generation-nebulizer-for-the-tyvasoa-inhalation-system.html
|
|
|
Post by babaoriley on Oct 23, 2017 12:34:26 GMT -5
itell, I think you're off the charts with pumping with the post about the bidding war. I think most people realize it, though, and are not investing imprudently based on your comments.
|
|
|
Post by sportsrancho on Oct 23, 2017 12:40:08 GMT -5
itell, I think you're off the charts with pumping with the post about the bidding war. I think most people realize it, though, and are not investing imprudently based on your comments. I thought he was right on about Merck.
|
|
|
Post by promann on Oct 23, 2017 12:55:52 GMT -5
itellthefuture777 I understand your excitement, but please refrain from the unrealistic pumping. No offense but I can remember a lot of bashing that went unchallenged by anyone. All the chalanges that I can remember only came from other long members and the hard bashing continued.
|
|
|
Post by babaoriley on Oct 23, 2017 13:13:09 GMT -5
Sports, we've seen what one big pharma did with Afrezza (I know the counter argument re CEO switch, and I buy into that 95%, but still, those sales were anemic). As a result, I'm not counting a damn chicken yet. If Merck wants in, that's wonderful, and will almost surely be a near term catalyst (if I know MNKD, it will last about 24-48 hours!). If Merck wants to buy us, even better, that catalyst will endure till the sale closes!
Let's think back to, what, summer of 2016, remember when just about everyone felt they'd be disappointed if the scripts weren't up to at least 600 (some such number, anyway), by end of 2016?
I am very happy with all of today's news, and Mike is doing a wonderful job of addressing the biggest issue regarding the sustainability of the company. I am still curious to know if we sold some stock ATM over and above the $60 million raise.
And there is positive momentum building on the domestic marketing aspects. Not so sure about progress on the all-important insurance front, although I have no doubt they are working feverishly on that issue. Certainly, we've had some progress there, but it's pretty tricky to figure exactly what it means when one says "Anthem" is aboard. These big insurers have about a billion or two different plans, and just cuz Afrezza is on a formulary with a given company, doesn't mean they are on the most widely used plan formularies. At least, that's my understanding of such things, and would love it if someone could tell me different.
I believe this story has a very good chance of turning around, and I can even go for multi-billions (2 of them, to be precise), and I remain very much tied to the investment, and enjoy the board, and the characters hereon.
And, of course, Sports, you are the hardest worker of them all, and all that you do is greatly appreciated! It's amazing that you can do it all with just ten fingers, one mouth, two ears and limited electronic gear! I think I'd feel safer if you were the Secretary of Defense. Bravo!
|
|
|
Post by sportsrancho on Oct 23, 2017 13:47:04 GMT -5
itellthefuture777 I understand your excitement, but please refrain from the unrealistic pumping. No offense but I can remember a lot of bashing that went unchallenged by anyone. All the chalanges that I can remember only came from other long members and the hard bashing continued. I hear ya:-). But, I think there is a lot of bashing that never sees the light of day because of our hard working monitors.
|
|
|
Post by pguererro on Oct 23, 2017 21:56:44 GMT -5
Baba: you simply don’t know what you are talking about when it comes to the compensation package Mannkind offers to their employees. It’s more than competitive and would be very attractive to a long time high performing pharma rep.
|
|
|
Post by itellthefuture777 on Oct 24, 2017 9:15:48 GMT -5
Baba: you simply don’t know what you are talking about when it comes to the compensation package Mannkind offers to their employees. It’s more than competitive and would be very attractive to a long time high performing pharma rep. If they would drop the degree requirement and sales history requirement..I could work as a sales rep at MNKD..
|
|
|
Post by babaoriley on Oct 24, 2017 10:33:52 GMT -5
Baba: you simply don’t know what you are talking about when it comes to the compensation package Mannkind offers to their employees. It’s more than competitive and would be very attractive to a long time high performing pharma rep. P, you are completely right on your first sentence. Re your second sentence, that's extremely difficult for me to believe, but if Sports says you're knowledgeable in this area, then I'll accept your statement.
|
|
|
Post by rockstarrick on Oct 24, 2017 20:44:42 GMT -5
Baba: you simply don’t know what you are talking about when it comes to the compensation package Mannkind offers to their employees. It’s more than competitive and would be very attractive to a long time high performing pharma rep. If they would drop the degree requirement and sales history requirement..I could work as a sales rep at MNKD.. Yeah, degree, sales history, or 5+ years as a MNKD Long Shareholder. Our friggin warehouse would be M-T 😎
|
|